Neurenati Therapeutics
Canada
- Montréal, Québec
- 01/03/2024
- Seed
- $1,200,000
Neurenati develops novel therapies for GI rare diseases
- Industry Biotechnology Research
- Website https://www.neurenati.com/
- LinkedIn https://www.linkedin.com/company/neurenati/
Related People
Maxime RangerFounder
Canada -
Greater Montreal Metropolitan Area
Serial entrepreneur who turned into venture capitalist in the life science space, specialized in the drug development: oncology, hepatology, gastroenterology and metabolic conditions, such as NASH, Prader-Willi Syndrome, type-2 diabetes and obesity. MBA, Ph.D. chemist with a scientific background in Material Sciences, more particularly in polymer chemistry. Two postdoc internships oriented to drug delivery, formulation development and nanolithography. Experience now extended to due diligence investigation, drug hunting and start-up financing. Co-authors of 30+ scientific publications in international peer-reviewed journals and co-inventors of 9 PCT-patented technologies.
Specialties: CMC, formulation development, drug delivery, IND-enabling preclinical studies, clinical development strategies (Phase I & II). Pre-Seed, Seed, Series A/B Fundraising, Corporate affairs, licensing activities and IP strategy.
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)